Ace the APEA Predictor Test 2026 – Unlock Your Nursing Superpowers!

When a patient's Coomb's test is negative, it indicates that there are no antibodies against red blood cells present in the serum, suggesting that immune hemolysis is not occurring. In the context of maternal-fetal medicine, particularly with Rh incompatibility, the negative result on the Coomb's test is crucial for managing the mother's care during pregnancy.

Rhogam (Rho(D) immune globulin) is a medication given to Rh-negative mothers to prevent the development of antibodies against Rh-positive blood cells that may enter the maternal circulation, often during delivery or other situations like trauma or miscarriage. Administering Rhogam at 28 weeks of gestation and again within 72 hours after the birth of an Rh-positive infant is a standard preventative measure. By doing so, it effectively reduces the risks of hemolytic disease of the newborn in any subsequent pregnancies.

Thus, the recommendation to give Rhogam in the situation described is appropriate and aligns with established guidelines for maternal care in cases of Rh-negative mothers. This proactive treatment strategy helps ensure both maternal and fetal health in future pregnancies.